Jason Burdette is an experienced leader with more than 30 years in the pharmaceutical industry across process chemistry, formulation and process development, manufacturing, supply chain management, and technical operations. At Venatorx, Jason is the Senior Vice President of CMC and Technical Operations and is responsible for driving strategic innovation and operational excellence, building capability in development, manufacturing and supply chain to enable the next phase of growth for product launch and commercialization.

He joined Venatorx from Aimmune/Nestle Health Science, where he was a Senior Vice President and Head of Technical Operations. At Aimmune/Nestle Health Science, Jason was responsible for formulation and process development, analytical development, CMC, manufacturing science and technology, quality control, quality assurance, supply chain and product distribution. He was an active member of the Aimmune’s executive leadership team and the Nestle Health Science’ Global Technical Operations Leadership Team. Prior to Aimmune/ Nestle Health Science, Jason was the Senior Vice President of Technical Operations with Paratek Pharmaceuticals. During his time with Paratek, he was responsible for CMC, manufacturing and supply chain, manufacturing science and technology, analytical chemistry, and product distribution, He was also an active member of Paratek’s executive leadership team. Preceding his experience with Paratek, Jason was the Vice President of Supply Chain with Eagle Pharmaceuticals, where he led manufacturing, supply chain, distribution, and new product introduction. Before Eagle Pharmaceuticals, Jason spent over 10 years with Shire Pharmaceuticals, holding positions of increasing responsibility including Vice President of Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, and Global Product Director and Supply Chain Lead for the ADHD business. He was a member of the supply chain leadership team and the international commercial team among other key executive leadership teams within the business units.

Earlier in Jason’s career he worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals. Jason holds a bachelor’s degree in chemistry and MBA from West Virginia University.

Dr. Condon is Vice President, Chemistry at Venatorx Pharmaceuticals. He has been engaged in the discovery and development of bioactive compounds for over 25+ years. Prior to joining Venatorx, Dr. Condon served in multiple roles at TetraLogic Pharmaceuticals where he led a team of scientists in the identification and evaluation of small molecule antagonists of the Inhibitor of Apoptosis (IAP) family of proteins. Together with an international team of collaborators, scientists at TetraLogic uncovered the central role of the cellular IAP proteins in TNF signaling, inflammation, and tumor cell death that led to the discovery of birinapant, a first-in-class bivalent IAP antagonist. Prior to TetraLogic, Dr. Condon was Group Leader in Medicinal Chemistry at ViroPharma where his team invented the first HCV NS5B inhibitor to demonstrate efficacy in the humanized mouse model of HCV infection. Dr. Condon began his professional career at Rhône-Poulenc Rorer. His team at RPR determined the bioactive conformation of human parathyroid [1-34] and developed a number of anabolic peptides for the treatment of post-menopausal osteoporosis. Dr. Condon received his doctoral degree from the University of Pennsylvania following his dissertation with Professor Amos B. Smith III on the total synthesis of rapamycin and demethoxyrapamycin.

Dr. Dorr is Vice President, Clinical Science at Venatorx Pharmaceuticals, where she is responsible for planning and executing clinical development across Venatorx’s anti-infectives portfolio. Dr. Dorr has devoted her 30+ year career to drug development, designing and implementing Phase 1 to Phase 4 clinical trials primarily for anti-infective products at both big—and small—pharmaceutical companies.

Prior to joining Venatorx, Dr. Dorr was Product Development Team Leader and Clinical Lead, Infectious Diseases at Merck where her primary responsibility was leading the clinical development for ZINPLAVA (bezlotoxumab), a monoclonal antibody that binds to and neutralizes C. difficile toxin B. She additionally led the development teams for DIFICID (fidaxomicin), a macrolide antibiotic for treatment of C. difficile, and CUBICIN (daptomycin), a lipopeptide antibiotic for serious Gram-positive bacterial infections. Prior to Merck, Dr. Dorr was Senior Director, Global Medical Affairs at Wyeth where she was the program leader for Phase 4 trials supporting women’s healthcare and gastrointestinal therapeutic areas, and served as Pandemic Preparedness Advisor.

In addition to her big pharma experience, Dr. Dorr served as the development team project manager at Vicuron Pharmaceuticals for dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive bacterial infections. Prior to Vicuron, she had several roles at Rhône-Poulenc Rorer. As a senior research scientist, Dr. Dorr was responsible for clinical pharmacokinetic development for a quinolone antibiotic, ZAGAM (sparfloxacin), and subsequently joined the clinical research group where she managed Phase 1 and 3 trials for ZAGAM and several Phase 3b trials for SYNERCID (quinupristin/dalfopristin), an antibiotic for serious Gram-positive infections. She also worked at Parke-Davis where she was responsible for the design and implementation of preclinical and clinical pharmacokinetic research for several quinolone antibiotics.

Dr Dorr received her B.S., Pharmacy from the University of the Sciences in Philadelphia; her Ph.D. in Pharmaceutics with an emphasis on pharmacokinetics and drug metabolism from the University of North Carolina in Chapel Hill, N.C., and completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia.

Ms. Ellis has more than 25 years of GCP/GMP quality assurance experience, having worked in and set up analytical chemistry and quality control laboratories. Ms. Ellis has experience creating quality control and quality assurance systems for small biotech companies and has extensive experience managing contract-manufacturing facilities for drug substance and drug product manufacture, including injectable and solid oral dosage forms.

Prior to joining Venatorx Pharmaceuticals, Ms. Ellis was Head of Quality Assurance at TRACON, and Vice President of Quality Assurance at Trius Therapeutics, Inc. (acquired by Cubist Pharmaceuticals, Inc.) where she led the GxP Quality activities for development and commercialization of Sivextro^TM. Sivextro^TM was approved by the U.S. Food and Drug Administration in June 2014. Ms. Ellis started her career as an analytical chemist at Alliance Pharmaceuticals, and then moved to leading analytical and CMC project teams at Pfizer, Inc. In her career, she has led CMC and Quality groups in the development of compounds in a variety of therapeutic areas.

Ms. Ellis received a B.A. in Chemistry from the University of Delaware.

Dr. Emeigh Hart is Vice President, Non-Clinical Safety at Venatorx Pharmaceuticals, where she leads the company’s nonclinical efforts across discovery, preclinical and clinical stage programs. She is an experienced nonclinical drug development scientist with more than 25 years of experience in preclinical drug development, including the design, conduct and supervision of toxicology, pathology, toxicokinetic/ADME, pharmacology, and mechanistic/derisking studies performed internally, through contract research organizations and through academic collaborations, preparation of submission documents (IND through NDA/BLA) and interaction with regulatory authorities. She has held numerous senior management and executive level positions in established global pharmaceutical companies and small biopharmaceutics firms, where she has managed non-clinical drug development programs and regulatory submissions (IND through NDA/BLA) for small molecules and monoclonal antibodies as well as unusual biopharmaceuticals (peptides, aminosterols, oligonucleotides, non-antibody, non-recombinant proteins and gene therapy products) across a wide variety of therapeutic areas, including cardiovascular/metabolic diseases, anti-infectives, oncology, CNS, rheumatology/orthopedics, and ophthalmology.

Prior to joining Venatorx, Dr. Emeigh Hart was the Director of Experimental Pathology in the Nonclinical Drug Safety (US) department at Boehringer Ingelheim, where she managed the Development and Molecular Pathology groups and the Clinical Pathology and Histology laboratories that performed pathological evaluations in support of new chemical entities and biologics from Discovery through full Development.  Before Boehringer Ingelheim, Dr. Emeigh Hart was the Vice President, Preclinical Development at Intrexon Corporation; Senior Director, Non-Clinical Development at Auxilium Pharmaceuticals; Senior Director, Safety Assessment at Genaera Corporation and held various roles at AstraZeneca, Bristol-Myers Squibb, DuPont Pharmaceuticals and Pfizer. Dr. Emeigh Hart is board certified in both Anatomic and Clinical Pathology through the American College of Veterinary Pathologists and in General Toxicology through the American Board of Toxicology; she is also a Eurotox Registered Toxicologist (peer recognized expert in toxicology through the UK Registry of Toxicology). She holds a Ph.D. from The University of Connecticut, a V.M.D. from the University of Pennsylvania School of Veterinary Medicine, and a B.S., Animal Science from The Pennsylvania State University. Dr. Emeigh Hart is an Adjunct Associate Professor (Pathology) at the University of Pennsylvania School of Veterinary Medicine.

Paul has spent nearly 20 years in the biopharmaceutical industry developing anti-infectives. Since 2019, he has worked at Venatorx Pharmaceuticals, developing cefepime-taniborbactam and ceftibuten-ledaborbactam. Before joining Venatorx Pharmaceuticals, Paul worked at Paratek Pharmaceuticals, Actelion Clinical Research and Wyeth/Pfizer, working on the development of antibacterials including omadacycline and tigecycline.

Prior to joining the industry, Paul was a Clinical Assistant Professor of Internal Medicine and Infectious Diseases at the University of Pennsylvania in Philadelphia, focusing on infection control, antimicrobial management, and patient care. Paul received his B.S. from the University of Notre Dame, his M.D. from Northwestern University, and completed his Internal Medicine and Infectious Diseases training at the University of Pennsylvania.

At Venatorx, Mr. Girard provides strategic, financial, and business development leadership to drive and maximize the value creation strategy for the clinical and preclinical antibacterial and antiviral programs.

Mr. Girard is a seasoned biopharmaceutical executive with multiple product approvals and launches over his 25 years of experience in strategic planning, corporate development, clinical development, and business development. He has extensive partnering experience having completed collaborations, licenses, acquisitions, and spinouts by and between leading pharmaceutical and biotech companies. Prior to joining Venatorx, he was the Chief Business Officer at GlycoMimetics where he was responsible for corporate strategy, partnering, and managing the company's corporate and institutional alliances supporting the development of uproleselan. Previously, he held the position of Vice President, Technical Assessment and Senior Director for Business Development at Shire Pharmaceuticals to build the product pipeline and support Shire’s strategic venture arm through investments. Of note, he played an instrumental role in the acquisition of Transkaryotic Therapies (now the foundation of Takeda’s Rare Disease Business Unit), Noven Pharmaceuticals, Ferrokin Biosciences, and numerous licensing deals (e.g., Sangamo Biosciences; Santaris). Armand received his undergraduate degree from Lehigh University and a M.B.A, from St Joseph’s Haub School of Business Executive Pharmaceutical Marketing Program.

Dr. Moeck is Senior Vice President, Microbiology at Venatorx Pharmaceuticals where he is responsible for ensuring comprehensive and timely characterization of investigational agents via clinical microbiology studies. He has spent over 15 years in antibacterial drug discovery and development, leading cross-functional teams or as a team member advancing the long-acting lipoglycopeptide oritavancin through nonclinical IND-enabling studies and Phase 1, 2 and 3 clinical studies, leading to its regulatory approval as Orbactiv^® in the U.S. in 2014 and the European Union in 2015. Dr. Moeck's microbiology team also contributed to the successful regulatory filing of meropenem/vaborbactam which was approved as Vabomere^TM by the U.S. Food and Drug Administration (FDA) in 2017. Prior to joining VenatoRx, Dr. Moeck was Vice President, Biology at The Medicines Company (acquired by Melinta Therapeutics) and Senior Director of Biology at Targanta Therapeutics (acquired by The Medicines Company).

Dr. Moeck has published over 50 papers in peer-reviewed journals, co-authored three book chapters, and is co-inventor on four patents relating to methods of treatment of bacterial infections. He received his Ph.D. in Microbiology and Immunology from McGill University in Montreal, Quebec and conducted post-doctoral research at the University of Paris XI on iron acquisition in gram-negative bacterial pathogens as a Fellow of the Natural Sciences and Engineering Research Council of Canada and the Ministry of Foreign Affairs, France.

Michael Miller serves as Senior Vice President of Global Regulatory Affairs and is responsible for the company’s regulatory strategy and operations. Mike has conducted infectious disease and immunology research for more than 30 years. After completing a postdoctoral fellowship studying the HIV integrase enzyme at The Salk Institute for Biological Studies, Mike began his pharmaceutical industry career at Merck. During 18 years working in antiviral drug discovery at Merck, Mike and his team advanced more than two dozen anti-HIV and anti-HCV compounds into clinical development, ultimately leading to marketing approvals for four drugs including the first-in-class HIV integrase inhibitor ISENTRESS®. He then moved to Oncology Regulatory Affairs at Merck to support early and late clinical development of immuno-oncology products. Mike served as Executive Director and led marketing application submissions to expand the oncology indications for Merck’s PD-1 inhibitor, KEYTRUDA^®. He later served as Vice President and Head of Global Regulatory Affairs at Idera Pharmaceuticals, and most recently was Senior Vice President and Head of Regulatory Affairs at AlloVir, Inc. Mike is a co-author on more than 100 peer-reviewed scientific publications. He holds a BA in Microbiology from the University of Kansas and a PhD in Immunology from Harvard University.

Ms. Nelson is Senior Vice President of Strategy Planning and Operations where she is responsible for management of alliances and delivery of R&D programs aligned with corporate strategy. Ms. Nelson has over 25 years of experience in the pharmaceutical industry spanning discovery, pre-clinical, early- and late-stage development across various therapeutic areas including anti-infectives, cardiovascular, respiratory/inflammation, and neuroscience. Previously, Ms. Nelson held various Project Management roles at AstraZeneca where she managed and led cross-functional teams in support of clinical development and NDA/MAA submissions, change management, data standardization, and data transparency policy initiatives. Prior to AstraZeneca, Ms. Nelson worked as a Project Manager and a medicinal chemist at DuPont Pharma. Ms. Nelson has a B.S. in Chemistry from Ursinus College and holds a Project Management Professional (PMP) certification.

Dr. Pevear is Founder and Senior Vice President of Biology and Grants Development at Venatorx Pharmaceuticals. He has over 25 years of experience in anti-infectives drug discovery and development, covering both anti-bacterials and anti-virals.

Prior to founding Venatorx, Dr. Pevear was the Director of Biology at Protez Pharmaceuticals (a subsidiary of Novartis Pharmaceuticals Corporation) where he co-led the team who advanced a first-in-class beta-lactamase inhibitor into preclinical development. Prior to Protez, Dr. Pevear spent two years with Novartis Pharmaceuticals in Cambridge, MA, where he directed the billion dollar collaboration with Alnylam Pharmaceuticals on ground-breaking “RNA interference” technology. He has also worked with Progenics Pharmaceuticals (Tarrytown, NY) where he directed research efforts in both Human immunodeficiency virus and Hepatitis C virus. In 1994 Dr. Pevear was a scientific team founding member of ViroPharma Inc. (Exton, PA). As the Director of Biology at ViroPharma, Dr. Pevear led a team of over 30 scientists working on a variety of anti-infective targets. He also served on the team that advanced a first-in-class inhibitor for the common cold viruses through NDA filing. This compound was discovered by Dr. Pevear’s laboratory during his time with Sterling Winthrop Research Institute (1988–1994).

Dr. Pevear has been involved in the advancement of more than a dozen compounds from the lab bench into clinical development. He has published over 80 papers in peer-reviewed journals and has written more than a half dozen reviews. Dr. Pevear has served as the Principal Investigator and/or written 6 SBIR-Advanced Technology awards and contributed to several others. He also served as an NIH Center for Scientific Review Special Emphasis Panel Member for AIDS SBIR applications in 2005.

Dr. Pevear received his Ph.D. in Viral Immunology from Rensselaer Polytechnic Institute in 1984, and was a Postdoctoral Fellow of the National Multiple Sclerosis Society in the lab of Dr. Howard Lipton (Northwestern University Medical School, Chicago, IL) from 1985–1988.

Mr. Sargent is Senior Vice President, Commercial Strategy at Venatorx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development. At Venatorx, Mr. Sargent is responsible for designing and executing the Company's commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.

Mr. Sargent has over 25 years of biopharmaceutical industry experience, including multiple product and line extension launches. Prior to joining Venatorx, he served as Vice President, Commercial Strategy at Nabriva where he led the launch and commercialization for Xenleta, a novel antibiotic approved for the treatment of community acquired bacterial pneumonia (CABP). Previously, Mr. Sargent held a variety of leadership roles at Auxilium Pharmaceuticals, including Vice President, Orthopedic Business Unit where he led the company's sales and marketing teams advancing XIAFLEX^® for the treatment of Dupuytren's contracture and development of additional pipeline indications. Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex. Mr. Sargent received his BA in Biology from Johns Hopkins University and an MBA from the University of Washington Foster School of Business.